Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome

By Brian Buntz | June 27, 2022

AcerThe clinical-stage pharma company Acer Therapeutics Inc. (Nasdaq:ACER) has begun screening patients for its Phase 3 DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical study of EDSIVO (celiprolol) to treat COL3A1-positive vascular Ehlers-Danlos syndrome (vEDS).

There are presently no FDA-approved drugs available for vEDS, which is associated with a risk of internal bleeding, internal injuries and aneurysms.

The study will determine whether the Beta 1 adrenergic receptor antagonist celiprolol reduces the likelihood of vEDS-related clinical events needing medical attention. Such events, including cardiac or arterial events, uterine rupture or intestinal rupture, can sometimes be fatal.

Vascular Ehlers-Danos syndrome is relatively rare, affecting between 6,000 and 8,000 people in the U.S., according to the VEDS Movement.

To optimize recruiting, Acer Therapeutics will use a decentralized study design. The company aims to recruit roughly 150 participants randomized 2:1 to receive celiprolol or a placebo.

The company expects the trial duration to be 3.5 years, with an interim analysis scheduled for 24 months after enrollment is completed.

The prospective DiSCOVER study will be randomized, double-blind and placebo-controlled, with an independent adjudication committee.

Eligible participants will have genetically confirmed COL3A1-positive vEDS.

The COL3A1 gene guides the production of instructions for making type III collagen.

In 2015, celiprolol received orphan drug designation for vEDS from FDA in 2015.

Acer filed a new drug application for the indication in 2018, but in 2019, Acer received an FDA Complete Response Letter (CRL).

In April 2022, however, FDA granted celiprolol Breakthrough Therapy designation for COL3A1-positive vEDS.

ACER shares were up 18.84% to $1.45 in mid-day trading.


Filed Under: Cardiovascular, clinical trials, Drug Discovery
Tagged With: Acer Therapeutics, celiprolol, COL3A1, DiSCOVER, vascular Ehlers-Danlos syndrome
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

ChemoCentryx/Amgen
Amgen to pay almost $4B for ChemoCentryx
Astellas Pharma in the Drug Discovery & Development Pharma 50
FDA places clinical hold on Astellas clinical trial focused on Pompe disease
AstraZeneca
AstraZeneca’s Farxiga met primary endpoint in Phase 3 heart failure trial 
Janssen
Janssen reports positive clinical trial data for its Xarelto to treat PAD effects

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50